Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger
Recce Pharmaceuticals (ASX:RCE) has been on a tear this year. It's developing anti-infective, R327, with clinical results across Diabetic Foot Infection, Acute Bacterial Skin & Skin Structure Infection, and, Urosepsis/UTIs which point to a potential commercial value proposition. It also has a recent key relationship in Indonesia.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
Tag | Subject | ||||||
---|---|---|---|---|---|---|---|
APK | Ann: Removal from Official List COB 29/10/13 | 29/10/13 | 0 | 1.4K | |||
|
|||||||
AGK +APK | Ann: APG: Offer Closed | 15/10/13 | 0 | 1.8K | |||
|
|||||||
APK | Ann: Change in substantial holding | 14/10/13 | 0 | 1.2K | |||
|
|||||||
AGK +APK | Ann: Change in substantial holding from AGK | 04/10/13 | 0 | 1.3K | |||
|
|||||||
AGK +APK | Ann: AGK: Section 630(3) Notice of status of defe | 03/10/13 | 0 | 1.7K | |||
|
|||||||
APK | Ann: Appendix 3B | 15:42 | 0 | 655 | |||
|
|||||||
AGK +APK | Ann: Change in substantial holding from AGK | 01/10/13 | 0 | 960 | |||
|
|||||||
APK | Ann: Suspension from Official Quotation at close | 27/09/13 | 0 | 661 | |||
|
See All Discussions